PMC7154275_01
a, b Abdominal contrast-enhanced CT findings before chemotherapy with cytotoxic and molecular targeted drugs. Low-density areas (white arrows) suspected of being peritoneal dissemination were detected.
cro-0013-0200-g01.jpg
PMC7154275_01_cro-0013-0200-g01.jpg
F1
Then, 1.5 years after the hepatectomy, peritoneal metastases were detected by abdominal contrast-enhanced CT (Fig. 1).
a, b Abdominal contrast-enhanced CT findings after 5 cycles of chemotherapy with cytotoxic and molecular targeted drugs. The size of peritoneal dissemination (white arrows) had increased.
cro-0013-0200-g02.jpg
PMC7154275_01_cro-0013-0200-g02.jpg
F2
However, as her disease progressed despite these treatments (Fig. 2), she was started on pembrolizumab at 200 mg because the primary resected specimen revealed that the tumor was MSI-high.
Head MRI findings. There was no tumor in the pituitary gland (white arrow).
cro-0013-0200-g03.jpg
PMC7154275_01_cro-0013-0200-g03.jpg
F3
The magnetic resonance imaging (MRI) findings revealed no remarkable findings in the pituitary gland or hypothalamus (Fig. 3).
a, b Abdominal contrast-enhanced CT findings after 5 cycles of chemotherapy with pembrolizumab. The size of peritoneal dissemination (white arrows) was unchanged.
cro-0013-0200-g04.jpg
PMC7154275_01_cro-0013-0200-g04.jpg
F4
After 5 cycles of pembrolizumab, carcinoembryonic antigen levels were within the normal range, and CT showed that the size of the peritoneal dissemination had progressed slightly (Fig. 4).